Insmed Incorporated (INSM), a biopharmaceutical company, is showing positive developments in its product portfolio. The company reiterated its 2023 guidance, expecting revenue between $295-305 million, with strategic plans to expand the use of its ARIKAYCE product. Encouraging Phase 2 data for its TPIP drug, used in pulmonary hypertension treatment, highlights...
NASDAQ:INSM earning coming up Thursday but one to keep an eye on. Nice volume pattern ahead of that event.
NASDAQ:INSM Possible Scenario: LONG Evidence: Price Action, Money Flow Period: Less than two months. TP1: 28.5$ TP2: 29.5$ TP3: 31$ *This is my idea and could be wrong 100%.
I see a repeating divergence in INSM for a decent short play after this market maker finishes with a target of 7.50
Hey guys, INSMED is in a bullish push with high volume buy executed and a water-carrying candle shape followed by short legs. The TIMEFRAME M1 shows us a kind of hammer candle with a high negotiated sales volume, it wanted to bounce back from the bollinger base. But it was a failure passing on its low point to come back to test the base and the top of the...
Biotech play that's been consolidating in a tight manner for 3 weeks. Looks ready to breakout.
Hello again! Taking a long in INSM at 39.84 with a modest target of 41.84!
INSM putting in a nice bull flag after earnings run up on strong volume. Entry through $35 with SL just below all the consolidation.
Broke out from its downtrend once it hit its support and is now above it EMA it should now go up and test the resistance level.
1. Not up three days in a row 2. Linear move up prior to consolidation 3. Young Trend 4. No breakouts or breakdowns during consolidation phase 5. Clean and low volatility consolidation ***see roboticinvesting.com for more details on Momentum Surge
Did we miss the short since it kept topping out?? We did have a target on the short to close the gap. The long may not have been so obvious, with an exit at the 2nd arrow and red horizontal....
Looks like it could be about to exhale some heat to the upside.